RT @NephroSeeker: Trying to get over our own renalism, if we are peeking at PCSK9 inhibitors we can see, they are more efficient as lower t…
Trying to get over our own renalism, if we are peeking at PCSK9 inhibitors we can see, they are more efficient as lower the eGFR is 🔗 https://t.co/jI0soJKAvA https://t.co/iCekOQp1Eu
Great news! A recent study in the Journal of @ACCinTouch shows that evolocumab safely reduces risk for CV events in #CKD. Read it here: https://t.co/Jg09zqdghP https://t.co/F3gzzWzou2
RT @EstebanDL: Subanálisis de FOURIER en pacientes con insuficiencia renal Evolocumab vs placebo La droga en este grupo de pacientes dismin…
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
RT @EstebanDL: Subanálisis de FOURIER en pacientes con insuficiencia renal Evolocumab vs placebo La droga en este grupo de pacientes dismin…
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
Subanálisis de FOURIER en pacientes con insuficiencia renal Evolocumab vs placebo La droga en este grupo de pacientes disminuyó LDL y fue igual de segura a corto plazo Mortalidad? En estadío 3 retrasa a predominio de NO CARDIOVASCULAR, después aumenta htt
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
RT @JACCJournals: LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Re…
LDL-C lowering and relative clinical efficacy and safety of evolocumab vs. placebo were consistent across #CKD groups. Read more from the FOURIER Trial in this week's #JACC. https://t.co/c12H4wj8BV https://t.co/iIDxwOFXAw
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. https://t.co/du8RDKk1wc
CKD patients derive a similar relative risk reduction to but greater absolute risk reduction than those with preserved kidney function with evolocumab. Secondary analysis of the FOURIER Trial by @DCharytan https://t.co/6VlFBs9qMx
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
RT @joscarlor2: Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with mor…
RT @joscarlor2: Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with mor…
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. https://t.co/vo3TyZQvch
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
RT @JACCJournals: Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo accord…
Data on #PCSK9 inhibition in #CKD is limited. New study in #JACC compares the outcomes with evolocumab and placebo according to kidney function. https://t.co/gyWgJSugyr https://t.co/qJ8UqY2OuJ
In a new analysis from FOURIER trial involving patients with ASCVD and CKD, evolocumab is safe and effective across all CKD stages with a greater numerical reduction in CV death, MI, and stroke in those with more advanced CKD #cardiotwitter #FOAMed #JACC h
RT @krychtiukmd: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournal…
RT @krychtiukmd: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournal…
RT @krychtiukmd: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournal…
RT @krychtiukmd: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournal…
RT @krychtiukmd: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournal…
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial https://t.co/UqPSo0Qo3Y
RT @krychtiukmd: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournal…
RT @krychtiukmd: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournal…
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - important subanalysis in @JACCJournals #Cardiology #Cardiotwitter https://t.co/IJI8gOQchs https://t.co/JFrzE4uwUk